Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. It focuses on the development of products for the pharmaceutical treatment of glaucoma.

The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina.

Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.

Irvine, US
Size (employees)
70 (est)
Aerie Pharmaceuticals was founded in 2005 and is headquartered in Irvine, US

Key People at Aerie Pharmaceuticals

Richard J. Rubino

Richard J. Rubino

Chief Financial Officer
Casey C. Kopczynski

Casey C. Kopczynski

Chief Research Officer and Co-Founder
Gerald D. Cagle

Gerald D. Cagle

COO, Cognoptix Inc.; Former SVP, Research & Development; CSO, Alcon Laboratories Inc.
Thomas A. Mitro

Thomas A. Mitro

President and Chief Operating Officer
Dennis Henner

Dennis Henner

Managing Director Clarus Ventures
Murray Goldberg

Murray Goldberg

Chief Financial Officer Regeneron Pharmaceuticals, Inc.

Aerie Pharmaceuticals Office Locations

Aerie Pharmaceuticals has offices in Irvine, Bedminster Township
Irvine, US
Bedminster Township, US

Aerie Pharmaceuticals Metrics

Aerie Pharmaceuticals Summary

Market capitalization

$1.6 b

Closing share price

Aerie Pharmaceuticals's current market capitalization is $1.6 b.

Aerie Pharmaceuticals Market Value History

We estimate that Aerie Pharmaceuticals's current employees are approximately 23% female and 77% male.

Aerie Pharmaceuticals Company Life

You may also be interested in